Source-grounded facts extracted from MetaVia Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
MetaVia Inc. shareholders approved To authorize one or more adjournments of the Annual Meeting to solicit additional proxies in the event there are insufficient votes to approve Proposals 3 and 4 at the 2026-06-08 meeting.
“The stockholders approved the Adjournment Proposal.”
MetaVia Inc. shareholders approved To approve the First Amendment to the 2022 Equity Incentive Plan to increase the aggregate number of shares of Common Stock that may be issued pursuant to awards by 200,000 shares of Common Stock at the 2026-06-08 meeting.
“The stockholders approved the Equity Plan Proposal.”
MetaVia Inc. shareholders approved To approve an amendment to the Company's Third Amended and Restated Certificate of Incorporation, as amended, to effect a reverse split of the Company's outstanding Common Stock at a ratio in the range of 1-for-5 to 1-for-22 to be determined at the discretion of the Company's Board of Directors at the 2026-06-08 meeting.
“The stockholders approved the Reverse Stock Split Proposal.”
MetaVia Inc. shareholders approved To ratify the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-08 meeting.
“The stockholders ratified the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
MetaVia Inc. shareholders approved To elect two Class I directors, each to serve a three-year term until the 2029 annual meeting of stockholders and until the election and qualification of such director's successor, or such director's earlier death, resignation, or removal at the 2026-06-08 meeting.
“D. Gordon Strickland and James P. Tursi, M.D. were elected as Class I directors to serve until the 2029 annual meeting of stockholders.”
MetaVia Inc. reported financial results for the first quarter ended March 31, 2026.
“issued a press release announcing its financial results for the first quarter ended March 31, 2026”
MetaVia Inc. reported financial results for the year ended December 31, 2025.
“On March 26, 2026, MetaVia Inc. issued a press release announcing its financial results for the year ended December 31, 2025 and providing a corporate update.”
MetaVia Inc. entered into Underwriting Agreement with Ladenburg Thalmann & Co. Inc. valued at Issued and sold 614,840 Class A Units at $3.10 per unit and 1,998,704 Class B Units at $3.099 per un (effective 2026-01-15).
“On January 15, 2026, MetaVia Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with Ladenburg Thalmann & Co. Inc. (the “ Underwriter ”), pursuant to which the Company issued and sold, in an underwritten public offering by the Company (the “ Public Offering ”), (i) 614,840 Class A Units (the “ Class A Units ”), with each Class A Unit consisting of (A) one share of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), (B) 1.5 Series C Common Warrants to purchase 1.5 shares of Common Stock (the “ Series C Common Warrants ”), and (C) 1.5 Series D Common Warrants to purchase 1.5 shares of Common Stock, at a price of $3.10 per Class A Unit, and (ii) 1,998,704 Class B Units (the “ Class B Units ”), with each Class B Unit consisting of (A) one pre-funded warrant (the “ Pre-Funded Warrants ” and, together with the Series C Common Warrants and the Series D Common Warrants, the “ Warrants ”) to purchase one share of Common Stoc”
MetaVia Inc.: Amendment to Certificate of Incorporation to effect a 1-for-11 reverse stock split of common stock (effective 2025-12-04).
“On December 2, 2025, the Company filed with the Secretary of State of the State of Delaware (the “Delaware Secretary of State”) a Certificate of Amendment to its Certificate of Incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split.”
MetaVia Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5810(c)(3)(A)).
“November 26, 2025, the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to May 26, 2026 to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Company intends to continue actively monitoring the closing bid price for the Company’s common stock between now and May 26, 2026, and will consider available options to resolve the deficiency, including effecting a reverse stock split as stated above, and regain compliance with the Minimum Bid Price Requirement. If the Company does not re”
MetaVia Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“May 29, 2025, MetaVia Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company had a period”
MetaVia Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“May 29, 2025, MetaVia Inc. (the “Company” ) received a letter (the “Notice” ) from the Listing Qualifications Department (the “Staff” ) of The Nasdaq Stock Market LLC ( “Nasdaq” ) informing the Company that because the closing bid price of the Company’s common stock listed on Nasdaq was below $1.00 per share for the prior 30 consecutive business days, the Company is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement” ). In accordance with Nasdaq Marke”
MetaVia Inc.: Amended and restated bylaws to reflect the name change and other technical changes (effective 2024-11-29).
“the Board of Directors of the Company approved an amendment and restatement (the “Fourth Amended and Restated Bylaws”) of the Company’s Third Amended and Restated Bylaws, effective as of November 29, 2024. The Fourth Amended and Restated Bylaws reflect the Name Change, as well as certain other technical changes.”
MetaVia Inc.: Changed legal name from NeuroBo Pharmaceuticals, Inc. to MetaVia Inc (effective 2024-11-29).
“On November 15, 2024, NeuroBo Pharmaceuticals, Inc. (the “Company” or the “Registrant”) filed a Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation (“Certificate of Amendment”) with the Secretary of State of the State of Delaware to change the legal name of the Company from “NeuroBo Pharmaceuticals, Inc.” to “MetaVia Inc.,” effective as of November 29, 2024.”
MetaVia Inc. reported financial results for first quarter ended March 31, 2024.
“On May 9, 2024, NeuroBo Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ended March 31, 2024 and providing a corporate strategic update.”
MetaVia Inc. reported financial results for the year ended December 31, 2023.
“NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2023”
Marshall H. Woodworth was appointed as Chief Financial Officer at MetaVia Inc..
“On March 1, 2024, the Board of Directors (the “Board” ) of NeuroBo Pharmaceuticals, Inc. (the “Company” ) appointed Mr. Marshall H. Woodworth, age 66, as the Company’s Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective as of March 1, 2024.”
MetaVia Inc. reported financial results for the third quarter ended September 30, 2023.
“On November 13, 2023, NeuroBo Pharmaceuticals, Inc. (the “Company” ) issued a press release announcing its financial results for the third quarter ended September 30, 2023 and providing a corporate update.”
James P. Tursi, M.D. was appointed as Director at MetaVia Inc..
“On November 1, 2023, the Board of Directors (the “Board” ) of NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the “Company” ), on the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee” ), appointed James P. Tursi, M.D., effective immediately, to serve as a Class I director”
Marshall H. Woodworth was appointed as Acting Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer at MetaVia Inc..
“On October 25, 2023, the Board of Directors (the “Board” ) of NeuroBo Pharmaceuticals, Inc. (the “Company” ) appointed Mr. Marshall H. Woodworth as the Company’s Acting Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective as of October 27, 2023.”
Na Yeon (Irene) Kim resigned as Director at MetaVia Inc..
“On September 18, 2023, Ms. Na Yeon (Irene) Kim provided notice of her resignation from the Board of Directors (the “Board”) of NeuroBo Pharmaceuticals, Inc. (the “Company”), effective immediately.”
MetaVia Inc. incurred lease obligation with Alewife Properties LLC maturing three (3) years.
“On August 23, 2023, NeuroBo Pharmaceuticals, Inc. (the “Company” ) entered into a Standard Form Lease Agreement (the “Lease Agreement” ) with Alewife Properties LLC (the “Landlord” ), to lease certain office space of approximately 2,441 square feet located at 177 Huntington Avenue, Suite 1732, Boston, Massachusetts, 02115, also known as 545 Concord Avenue (the “Premises” ).”
Hyung Heon Kim was appointed as Chief Executive Officer, President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer at MetaVia Inc..
“appointed Mr. Hyung Heon Kim, a member of the Board, as the Company’s Chief Executive Officer, President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer effective as of August 11, 2023.”
MetaVia Inc. reported financial results for the second quarter ended June 30, 2023.
“NeuroBo Pharmaceuticals, Inc. (the “Company” ) issued a press release announcing its financial results for the second quarter ended June 30, 2023”
MetaVia Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“February 8, 2023, NeuroBo Pharmaceuticals, Inc. (the “Company” ) received a letter (the “Notice” ) from the Listing Qualifications Department (the “Staff” ) of the Nasdaq Stock Market ( “Nasdaq” ) informing the Company that because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement” ). In accordance with Nasdaq Listing Rule”
MetaVia Inc. shareholders approved Authorization of one or more adjournments to solicit additional proxies if insufficient votes to approve reverse split proposal at the 2023-06-28 meeting.
“Proposal 4— Approval to authorize one or more adjournments of the Annual Meeting to solicit additional proxies in the event there are insufficient votes to approve Proposal 3 described above. Votes For Votes Against Votes Abstain 18,644,657 717,732 21,357”
MetaVia Inc. shareholders approved Approval of an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio in the range of 1-for-5 to 1-for-8 at the 2023-06-28 meeting.
“Proposal 3— Approval of an amendment to the Company’s Certificate of Incorporation to effect a reverse split of the Company’s outstanding common stock at a ratio in the range of 1-for-5 to 1-for-8 to be determined at the discretion of the Company’s Board of Directors, whereby each outstanding 5 to 8 shares would be combined, converted and changed into 1 share of the Company’s common stock. Votes For Votes Against Votes Abstain 18,447,440 929,062 7,244”
MetaVia Inc. shareholders approved Ratification of the appointment of BDO USA, LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-28 meeting.
“Proposal 2— Ratification of the Appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. Votes For Votes Against Votes Abstain 19,014,374 311,654 57,718”
MetaVia Inc. shareholders approved Election of two Class I directors at the 2023-06-28 meeting.
“Proposal 1— Election of two Class I directors, each to serve three-year terms until the 2026 annual meeting of stockholders and until the election and qualification of his or her successor, or such director’s earlier death, resignation, or removal. Class I Nominees Votes For Votes Withheld Broker Non-Votes Na Yeon (Irene) Kim 16,263,684 128,573 2,991,489 D. Gordon Strickland 16,220,250 172,007 2,991,489”
Mark A. Glickman was appointed as Class III director at MetaVia Inc..
“On May 11, 2023, the Board of Directors (the “Board” ) of NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the “Company” ), on the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee” ), appointed Mark A. Glickman, effective immediately, to serve as a Class III director”
MetaVia Inc. reported year ended December 31, 2022 results: net income Net Loss for the year ended December 31, 2022 was $14.0 million, EPS $5.43 per basic and diluted share.
“Net Loss for the year ended December 31, 2022 was $14.0 million, or $ 5.43 per basic and diluted share”
MetaVia Inc. shareholders approved Say-on-Frequency Proposal (advisory vote on frequency of say-on-pay votes).
“in an advisory vote held at the Annual Meeting on the Say-on-Frequency Proposal, the Company’s stockholders expressed their preference for a Say-on-Pay Vote to be conducted every three years.”
Joseph Hooker was appointed as Interim Chief Executive Officer, President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer at MetaVia Inc..
“On January 12, 2023, the Board appointed Joseph Hooker as the Company’s Interim Chief Executive Officer, President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer, effective as of January 12 , 2023.”
Gil Price resigned as Chief Executive Officer and President at MetaVia Inc..
“On January 12, 2023, Gil Price, M.D. resigned as Chief Executive Officer and President of NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the “Company” ), effective immediately.”
MetaVia Inc. shareholders approved Authorization of adjournments of the Special Meeting at the 2022-12-22 meeting.
“Proposal 4—Authorization of one or more adjournments of the Special Meeting to solicit additional proxies in the event there are insufficient votes to approve Proposals 1, 2 or 3 Votes For Votes Against Votes Abstain 362,373 10,891 1,702”
MetaVia Inc. shareholders approved Approval of the NeuroBo Pharmaceuticals, Inc. 2022 Equity Incentive Plan at the 2022-12-22 meeting.
“Proposal 3— Approval of the NeuroBo Pharmaceuticals, Inc. 2022 Equity Incentive Plan Votes For Votes Against Votes Abstain 362,390 10,863 1,713”
MetaVia Inc. shareholders approved Approval of issuance of shares upon exercise of Series A and Series B Warrants at the 2022-12-22 meeting.
“Proposal 2— Approval pursuant to Nasdaq Listing Rule 5635(d) and Nasdaq’s interpretations and guidance thereunder, the issuance of shares of the Company’s common stock upon the exercise of the Company’s Series A Warrants and Series B Warrants issued to investors in the Company’s underwritten offering that closed on November 8, 2022 Votes For Votes Against Votes Abstain 365,882 7,416 1,668”
MetaVia Inc. shareholders approved Approval of issuance of shares in connection with License Agreement and Securities Purchase Agreement at the 2022-12-22 meeting.
“Proposal 1— Approval, in accordance with applicable Nasdaq rules, of the issuance of shares of common stock in respect of the License Agreement, and pursuant to the Securities Purchase Agreement, including upon the conversion of shares of the Company’s Series A Convertible Preferred Stock issued to Dong-A pursuant to the terms and conditions of the License Agreement and the Securities Purchase Agreement, the exercise of warrants issued to Dong-A pursuant to the terms and conditions of the Securities Purchase Agreement and in respect of various commercial and regulatory milestone payments that may become payable in the future to Dong-A under the terms and conditions of the License Agreement that the Company may elect to pay to Dong-A in shares of the Company’s common stock Votes For Votes Against Votes Abstain 366,971 6,112 1,883”
MetaVia Inc.: Filed Certificate of Designations for Series A and Series B Convertible Preferred Stock (effective 2022-11-04).
“On November 4, 2022, the Company filed the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “ Series A Certificate of Designations ”) and the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (the “ Series B Certificate of Designations ,” and together with the Series A Certificate of Designations, the “ Certificate of Designations ”) with the Secretary of State of the State of Delaware.”
MetaVia Inc. entered into Warrant Agency Agreement with American Stock Transfer & Trust Company LLC valued at governs warrants sold in Public Offering (effective 2022-11-08).
“On November 8, 2022, the Company also entered into a warrant agency agreement with the Company’s transfer agent, American Stock Transfer & Trust Company LLC, who will act as warrant agent for the Company, setting forth the terms and conditions of the Warrants sold in the Public Offering (the “ Warrant Agency Agreement ”).”
MetaVia Inc. entered into Underwriting Agreement with Ladenburg Thalmann & Co. Inc. valued at net proceeds approximately $15.1 million (effective 2022-11-04).
“On November 4, 2022, NeuroBo Pharmaceuticals, Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with Ladenburg Thalmann & Co. Inc. (the “ Underwriter ”), pursuant to which the Company issued and sold, in an underwritten public offering by the Company (the “ Public Offering ”), (a) 2,397,003 Class A Units (the “ Class A Units ”), with each Class A Unit consisting of (i) one share of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), (ii) one warrant to purchase one share of Common Stock exercisable following approval of the Company’s stockholders (each, a “ Series A Warrant ”) and (iii) one warrant to purchase one share of Common Stock exercisable following approval of the Company’s stockholders (each, a “ Series B Warrant ,” and together with the Class A Series A Warrants, the “ Warrants ”), with each Class A Unit offered to the public at an offering price of $3.00 per Class A Unit and (b) 2,602,997 Class B Units”
D. Gordon Strickland was appointed as Class I Director at MetaVia Inc..
“appointed D. Gordon Strickland, effective immediately, to serve as a Class I director to hold office for a term expiring at the Company’s 2023 annual meeting”
Andrew I. Koven was elected as Chairman of the Board at MetaVia Inc..
“Andrew I. Koven, a current director of the Company was elected Chairman of the Board”
Douglas J. Swirsky resigned as Director at MetaVia Inc..
“Mr. Douglas J. Swirsky provided notice of his resignation from the Board of Directors”
Richard Kang resigned as Chief Executive Officer and President at MetaVia Inc..
“Richard Kang, Ph.D. resigned from his positions as Chief Executive Officer and President of the Company, effective as of November 3, 2021”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.